Exhibit 99.1

		For the Three Months Ended September 30,
		2022				2021
Net loss		$	(995	)		$	(521	)
Adjustments:
Depreciation and amortization			1,311				983
Amortization of right-of-use asset			67				87
Loss on disposal of property and equipment			17				10
Income tax expense			-				4
Interest expense, net			209				52
Non-GAAP EBITDA			609				615
Stock-based compensation			455				320
Non-GAAP adjusted EBITDA		$	1,064			$	935

		Three Months Ended September 30,
		2022				2021
Gross domestic recurring billings		$	5,548			$	5,822
Co-Pay adjustments			(188	)			(199	)
Other discounts			(40	)			(43	)
Deferred revenue from prior quarters			2,499				1,897
Deferral of revenue to future quarters			(2,309	)			(2,107	)
GAAP Recorded domestic revenue		$	5,510			$	5,370

		For the Three Months Ended September 30,
		2022				2021
Gross profit		$	5,799			$	5,376
Amortization of acquired intangible assets			507				144
Non-GAAP gross profit		$	6,306			$	5,520
Gross profit percentage			61.6	%			69.7	%
Non-GAAP gross profit percentage			67.0	%			71.6	%

		September 30, 2022				December 31, 2021
Assets		(unaudited)
Current assets:
Cash and cash equivalents		$	7,454			$	12,586
Restricted cash			1,361				-
Accounts receivable, net of allowance for doubtful accounts of $299 and $275 at September 30, 2022 and December 31, 2021, respectively			3,655				3,433
Inventories			5,662				3,489
Prepaid expenses and other current assets			621				462
Total current assets			18,753				19,970
Property and equipment, net			6,566				6,883
Operating lease right-of-use assets			836				638
Intangible assets, net			18,110				10,083
Goodwill			8,803				8,803
Other assets			167				216
Total assets		$	53,235			$	46,593
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable		$	4,369			$	2,822
Accrued expenses and other current liabilities			6,075				6,377
Deferred revenues			2,968				3,285
Current portion of operating lease liabilities			246				318
Current portion of contingent consideration			500				-
Total current liabilities			14,158				12,802
Long-term debt			7,435				7,319
Deferred revenues and other liabilities			280				400
Deferred tax liability			266				266
Operating lease liabilities net of current portion			674				392
Contingent consideration, net of current portion			8,622				-
Total liabilities			31,435				21,179
Stockholders' equity:
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized; no shares issued and outstanding			-				-
Common stock, $0.001 par value, 150,000,000 shares authorized; 34,723,046 and 34,364,679 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively			35				34
Additional paid-in capital			248,833				247,059
Accumulated deficit			(227,068	)			(221,679	)
Total stockholders' equity			21,800				25,414
Total liabilities and stockholders’ equity		$	53,235			$	46,593

		For the Three Months Ended September 30,
		2022				2021
Revenues, net		$	9,413			$	7,711
Cost of revenues			3,614				2,335
Gross profit			5,799				5,376
Operating expenses:
Engineering and product development			216				371
Selling and marketing			3,754				3,295
General and administrative			2,615				2,175
			6,585				5,841
Loss from operations			(786	)			(465	)
Other income (expense):
Interest expense			(244	)			(53	)
Interest income			35				1
			(209	)			(52	)
Loss before income taxes			(995	)			(517	)
Income tax expense			-				(4	)
Net loss		$	(995	)		$	(521	)
Net loss per share of common stock, basic and diluted		$	(0.03	)		$	(0.02	)
Weighted average shares of common stock outstanding, basic and diluted			34,723,046				34,150,438

		For the Nine Months Ended September 30,
		2022				2021
Revenues, net		$	25,559			$	20,920
Cost of revenues			10,639				7,070
Gross profit			14,920				13,850
Operating expenses:
Engineering and product development			588				1,158
Selling and marketing			11,516				9,387
General and administrative			7,599				7,085
			19,703				17,630
Loss from operations			(4,783	)			(3,780	)
Other income (expense):
Gain on debt extinguishment			-				2,028
Interest expense			(651	)			(109	)
Interest income			45				16
			(606	)			1,935
Loss before income taxes			(5,389	)			(1,845	)
Income tax expense			-				(12	)
Net loss		$	(5,389	)		$	(1,857	)
Net loss per share of common stock, basic and diluted		$	(0.16	)		$	(0.05	)
Weighted average shares of common stock outstanding, basic and diluted			34,708,606				33,944,321

		For the Nine Months Ended September 30,
		2022				2021
Cash flows from operating activities:
Net loss		$	(5,389	)		$	(1,857	)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Amortization of intangible assets			2,155				1,113
Amortization of operating lease right-of-use assets			248				261
Depreciation and amortization			1,816				1,576
Amortization of deferred financing costs and debt discount			116				-
Provision (recoveries) for doubtful accounts			24				(26	)
Stock-based compensation			1,275				1,563
Loss on disposal of property and equipment			52				73
Gain on debt extinguishment			-				(2,028	)
Deferred taxes			-				12
Changes in operating assets and liabilities:
Accounts receivable			(246	)			(181	)
Inventories			(1,616	)			219
Prepaid expenses and other assets			(110	)			(243	)
Accounts payable			1,547				(284	)
Accrued expenses and other liabilities			(267	)			858
Deferred revenues			(472	)			58
Operating lease liabilities			(236	)			(275	)
Net cash (used in) provided by operating activities			(1,103	)			839
Cash flows from investing activities:
Purchase of property and equipment			(2,037	)			(2,523	)
Cash paid in connection with TheraClear asset acquisition			(631	)			-
Cash paid in connection with Ra Medical asset acquisition			-				(3,473	)
Net cash used in investing activities			(2,668	)			(5,996	)
Cash flows from financing activities:
Proceeds from long-term debt			-				8,000
Payment of deferred financing costs			-				(133	)
Repayment of note payable			-				(7,275	)
Repayment of long-term debt			-				(500	)
Net cash provided by financing activities			-				92
Net decrease in cash, cash equivalents and restricted cash			(3,771	)			(5,065	)
Cash, cash equivalents and restricted cash, beginning of period			12,586				18,112
Cash, cash equivalents and restricted cash, end of period		$	8,815			$	13,047
Cash and cash equivalents		$	7,454			$	13,047
Restricted cash			1,361				-
		$	8,815			$	13,047
Supplemental disclosure of cash flow information:
Cash paid for interest		$	523			$	109
Supplemental disclosure of non-cash operating, investing and financing activities:
Change in operating lease right-of-use assets and liability due to amended lease		$	446			$	-
Inventories acquired in connection with TheraClear asset acquisition		$	71			$	-
Intangible assets acquired in connection with TheraClear asset acquisition		$	10,182			$	-
Contingent consideration issued in connection with TheraClear asset acquisition		$	9,122			$	-
Common stock issued in connection with TheraClear asset acquisition		$	500			$	-
Transfer of property and equipment to inventories		$	486			$	-
Fair value of warrants issued in connection with debt		$	-			$	585
Assumed deferred revenue in connection with Ra Medical asset acquisition		$	-			$	1,841